Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus doxorubicin versus doxorubicin for platinum-resistant recurrent ovarian cancer
ChiCTR2000030918Phase 4Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2016
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Rivoceranib and doxorubicin in ovarian cancer (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-free survival. Started Sep 2016; status: recruiting.
02
Drugs
Rivoceranibdoxorubicin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ChiCTR2000030918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030918.